氯吡格雷联合阿司匹林治疗小卒中或TIA的风险与获益:CHANCE试验的时间进程分析
基于CHANCE试验数据,分析氯吡格雷联合阿司匹林治疗小卒中或TIA的短期时间进程风险与获益。主要结局为新发缺血性卒中,安全结局为任何出血和中重度出血。结果显示联合治疗在前2周内数值上降低缺血性卒中风险,从第10天起联合治疗导致的任何出血例数超过其减少的新发卒中例数。结论认为尤其在前2周内,联合治疗降低卒中风险的获益超过出血风险。
要点
- 氯吡格雷联合阿司匹林在前2周内数值上降低新发缺血性卒中风险。
- 从第10天起,联合治疗导致的任何出血例数超过其减少的新发卒中例数。
- 联合治疗组与阿司匹林单药组的新发缺血性卒中均主要发生在第一周。
核心结论
- 与阿司匹林单药相比,氯吡格雷联合阿司匹林治疗小卒中或TIA患者,尤其在前2周内,降低卒中风险的获益可能超过出血风险。
研究设计与样本
- 基于CHANCE试验(氯吡格雷用于急性非致残性脑血管事件高危患者)的数据进行时间进程分析。
主要发现
- 联合治疗组204例新发缺血性卒中中,第一、二、三周分别发生145例(71.1%)、13例(6.4%)、12例(5.9%);阿司匹林单药组295例中分别发生223例(75.6%)、19例(6.4%)、8例(2.7%)。
- 联合治疗组60例出血中,第一、二、三周分别发生23例(38.3%)、15例(25.0%)、9例(15.0%);阿司匹林单药组41例中分别发生15例(36.6%)、8例(19.5%)、3例(7.3%)。
- 联合治疗在前2周内数值上降低缺血性卒中风险;从第10天起,联合治疗导致的任何出血例数超过其减少的新发卒中例数。
关键数值与推荐
- 主要结局为新发缺血性卒中;安全结局包括任何出血和中重度出血。
- 该研究提供Class II证据:对于小卒中或TIA患者,氯吡格雷联合阿司匹林在前2周内降低卒中风险超过阿司匹林单药的出血风险。
临床怎么用
- 对于小卒中或TIA患者,可考虑在前2周内使用氯吡格雷联合阿司匹林以降低卒中风险,同时需监测出血。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVE: To investigate the short-term time course risks and benefits of clopidogrel with aspirin in minor ischemic stroke or TIA. METHODS: Data were derived from the Clopidogrel in High-Risk Patients with Acute Nondisabling Cerebrovascular Events (CHANCE) trial. The primary outcome was a new ischemic stroke. Safety outcomes included any bleeding and moderate to severe bleeding. Time course analyses were performed for the outcomes of both stroke and bleeding. RESULTS: A total of 145 (71.1%), 13 (6.4%), and 12 (5.9%) of 204 new ischemic strokes in the clopidogrel-aspirin group vs 223 (75.6%), 19 (6.4%), and 8 (2.7%) of 295 in the aspirin alone group occurred at the first, second, and third week, respectively. A total of 23 (38.3%), 15 (25.0%), and 9 (15.0%) of 60 bleeding cases in the clopidogrel-aspirin group vs 15 (36.6%), 8 (19.5%), and 3 (7.3%) of 41 in the aspirin alone group occurred at the first, second, and third week, respectively. Clopidogrel-aspirin treatment numerically reduced the risk of ischemic stroke within the first 2 weeks. From the 10th day, the number of any bleeding cases caused by dual antiplatelets outweighed that of new stroke reduced by dual antiplatelets. CONCLUSIONS: Clopidogrel-aspirin treatment may have a benefit of reducing stroke risk outweighing the potential risk of increased bleeding especially within the first 2 weeks compared with aspirin alone in patients with minor stroke or TIA. CLINICALTRIALSGOV IDENTIFIER: NCT00979589. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that for patients with minor stroke or TIA, the reduction of stroke risk from clopidogrel plus aspirin within the first 2 weeks outweighs the risk of bleeding compared with aspirin alone.
引用
- Pan Y, Jing J, Chen W, et al. Risks and benefits of clopidogrel-aspirin in minor stroke or TIA: Time course analysis of CHANCE. Neurology. 2017. PMID: 28424269. doi:10.1212/WNL.0000000000003941
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。